Fernand Labrie
Publications
Page 4 of 8, showing 50 records out of 368 total, starting on record 151, ending on 200
| Publication | Category | Year |
|---|---|---|
| 153. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1992) Blockade of androgen action by combined treatment with a pure antiandrogen (Flutamide) and a 5α-reductase inhibitor (4-MA), in: Giuliani, L. et Puppo, P., eds: Urology, Bologna, Monduzzi Editore, pp 605-610. | Prostate Cancer | 1992 |
| 154. Pinault, S., Têtu, B., Gagnon, J., Monfette, G., Dupont, A., Labrie, F. (1992) Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination therapy with flutamide. Urology, 39: 254-261. | Prostate Cancer | 1992 |
| 155. Bélanger, A., Brochu, M., Lacoste, D., Noel, C., Labrie, F., Dupont, A., Cusan, L., Caron, S., Couture, J. (1991) Steroid glucuronides: human circulatory levels and formation by LNCaP cells. J. Steroid Biochem. Mol. Biol., 40: 593-598. | Prostate Cancer | 1991 |
| 156. de Launoit, Y., Veilleux, R., Dufour, M., Simard, J., Labrie, F. (1991) Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res., 51: 5165-5170. | Prostate Cancer | 1991 |
| 157. Dupont, A., Cusan, L., Gomez, J.-L., Thibeault, M.M., Tremblay, M., Labrie, F. (1991) Prostatic specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J. Urol., 146: 1064-1068. | Prostate Cancer | 1991 |
| 158. Labrie, C., Trudel, C., Li, S., Martel, C., Couët, J., Labrie, F. (1991) Combination of an antiandrogen and a 5a-reductase inhibitor: a further step towards total androgen blockade? Endocrinology, 129: 566-568. | Prostate Cancer | 1991 |
| 159. Labrie, F. (1991) Endocrine therapy for prostate cancer, in: Strauss, J.F., ed. Endocrinology and Metabolism Clinics of North America, Philadelphia, W.B. Saunders, pp 845-872. | Prostate Cancer | 1991 |
| 160. Labrie, F. (1991) Intracrinology. Mol. Cell. Endocrinol., 78: C113-C118. | Prostate Cancer | 1991 |
| 161. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Lacourcière, Y., Monfette, G., Emond, J. (1991) Maximal androgen blockade in prostate cancer: To-Day's Therapy of choice and 5-year clinical experience, in: Vickery, B.H. et Lunenfeld, B., eds: International Symposium on GnRH analogues in Cancer and Human Reproduction, The Netherlands, Kluwer Academic Publishers, pp 79-102. | Prostate Cancer | 1991 |
| 162. Simard, J., Veilleux, R., de Launoit, Y., Haagensen, D.E., Labrie, F. (1991) Stimulation of apoliprotein D secretion by steroids coincide with inhibition of cell proliferation in LNCaP prostate cancer cells. Cancer Res., 51: 4336-4341. | Prostate Cancer | 1991 |
| 163. Têtu, B., Srigley, J.R., Boivin, J.C., Dupont, A., Monfette, G., Pinault, S., Labrie, F. (1991) Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: a histopathologic and immunohistochemical study. Am. J. Surg. Pathol., 15: 111-120. | Prostate Cancer | 1991 |
| 164. Bélanger, C., Veilleux, R., Labrie, F. (1990) Stimulatory effects of androgens, estrogens, progestins and dexamethasone on the growth of the LNCaP human prostate cancer cells. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds. Steroid Formation, Degradation and Action in Peripheral, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 399-402. | Prostate Cancer | 1990 |
| 165. Candas, B., Lacoste, D., Normand, M., Labrie, F. (1990) Model of the distribution and metabolism of the gonadotropin-releasing hormone (GnRH) agonist [D-Trp6,Des-Gly-NH2(10)]GnRH ethylamide in man. J. Clin. Endocrinol. Metab. 70: 1046-1054. | Prostate Cancer | 1990 |
| 166. Dupont, A., Boucher, H., Cusan, L., Lacourcière, Y., Emond, J., Labrie, F. (1990) Octreotide and bromocriptine in patients with stage D2 prostate cancer who relapsed during treatment with Flutamide and castration. Eur. J. Cancer, 26: 770-771. | Prostate Cancer | 1990 |
| 167. Labrie, C., Simard, J., Poulin, M., Bélanger, A., Pelletier, G., Labrie, F. (1990) Influence of the duration of androgen deprivation on the sensitivity of the rat ventral prostate to dehydroepiandrosterone and androstenedione. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F. eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 392-394. | Prostate Cancer | 1990 |
| 168. Labrie, C., Simard, J., Zhao, H.F., Bélanger, A., Pelletier, G., Labrie, F. (1990) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F. eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 395-398. | Prostate Cancer | 1990 |
| 169. Labrie, C., Simard, J., Zhao, H.F., Pelletier, G., Labrie, F. (1990) Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Mol. Cell. Endocrinol., 68: 169-179. | Prostate Cancer | 1990 |
| 170. Labrie, F. (1990) Goserelin study criticized. Oncology Times, 10: 18-19. | Prostate Cancer | 1990 |
| 171. Labrie, F. (1990) Peripheral tissues are important sites of sex steroid formation in the human: a new field of endocrinology which extends from gene structure to therapy that prolongs life in prostate cancer. Physiol Canada, 13th Sarrazin Lecture, 21: 66-99. | Prostate Cancer | 1990 |
| 172. Labrie, F., Bélanger, A., Dupont, A., Pelletier, G., Luu-The, V., Simard, J., Cusan, L., Labrie, C., Lachance, Y., Poulin, R., Dupont, E., Zhao, H.F., Martel, C. (1990) Synthèse périphérique des androgènes chez l'homme. Génétique moléculaire du système et sa prise en compte dans le traitement du cancer de la prostate. Médecine/Sciences, 6: 261-267. | Prostate Cancer | 1990 |
| 173. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Emond, J., Monfette, G. (1990) Combination therapy with Flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience. J. Steroid Biochem. Mol. Biol., 37: 943-950. | Prostate Cancer | 1990 |
| 174. Lacoste, D., Bélanger, A., Labrie, F. (1990) Biosynthesis and degradation of androgens in human prostatic cancer cell lines. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds. Steroid Formation, Degradation and Action in Peripheral Tissues Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 389-391. | Prostate Cancer | 1990 |
| 175. Lacoste, D., Candas, B., Normand, M., Labrie, F. (1990) Model of the distribution and metabolism of a GnRH superagonist in dogs. Am. J. Physiol., 258: E468-E475. | Prostate Cancer | 1990 |
| 176. Pinault, S., Fortin, D., Gagnon, J., Têtu, B., Dupont, A., Labrie, F. (1990) La biopsie prostatique transrectale sous guide ultrasonore. Radiologie, 10: 313-317. | Prostate Cancer | 1990 |
| 177. Rousseau, L., Couture, M., Dupont, A., Labrie, F., Couture, N. (1990) Effect of combined androgen blockade with an LHRH agonist and Flutamide in one severe case of male exhibitionism. Can. J. Psychiatry, 35: 338-341. | Prostate Cancer | 1990 |
| 178. Bélanger, B., Bélanger, A., Labrie, F., Dupont, A., Cusan, L., Monfette, G. (1989) Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J. Steroid Biochem., 32: 695-698. | Prostate Cancer | 1989 |
| 179. Dupont, A., Labrie, F., Manhès, G., Bergeron, N., Cusan, L., Pinault, S., Bélanger, A., Boucher, M., Lacourcière, Y., Emond, J. (1989) Combination therapy with Flutamide and the LHRH agonist [D-Trp6, des-Gly-NH210]LHRH ethylamide in stage C prostatic carcinoma, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 89-102. | Prostate Cancer | 1989 |
| 180. Emond, J., Dupont, A., Cusan, L., Bergeron, N., Manhès, G., Labrie, F. (1989) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) as an alternative to transurethral resection of the prostate for urinary retention in prostate cancer, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, pp 103-108. | Prostate Cancer | 1989 |
| 181. Labrie, C., Simard, J., Marchetti, B., Pelletier, G., Zhao, H.F., Bélanger, A., Labrie, F. (1989) Conversion of precursor adrenal steroids into potent androgens in peripheral tissue, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 1-22. | Prostate Cancer | 1989 |
| 182. Labrie, C., Simard, J., Zhao, H., Bélanger, A., Pelletier, G., Labrie, F. (1989) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 124: 2745-2754. | Prostate Cancer | 1989 |
| 183. Labrie, F. (1989) Criteria of response of stage D2 prostate cancer [Letter to the Editor: Reply to Newling et al. re 24: 1869-78, 1988]. Eur. J. Cancer Clin. Oncol., 25: 1259-1260. | Prostate Cancer | 1989 |
| 184. Labrie, F. (1989) Medical treatment of prostate cancer. Drug Therapy, 19: 22-37. | Prostate Cancer | 1989 |
| 185. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Brochu, M., Turina, E., Pinault, S., Lacourcière, Y., Emond, J. (1989) Anti-hormone treatment in stage D2 prostate cancer patients relapsing under treatment with Flutamide and castration: addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br. J. Urol., 63: 634-638. | Prostate Cancer | 1989 |
| 186. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Lacourcière, Y., Bélanger, A., Monfette, G., Emond, J. (1989) Terapia combinada con flutamida y (D-TRP6)LH-RH etilamida en el cancer de prostata en estadio D2 sin tratamiento previo, in: Pontes, J.E., Mallo, N. et Zungri, E., eds: Cancer de Prostata, ulso Ediciones, Barcelona, Actualizaciones Urologicas, pp 73-86. | Prostate Cancer | 1989 |
| 187. Labrie, F., Dupont, A., Cusan, L., Labrie, C., Lacoste, D., Luu-The, V., Manhès, G., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Today's endocrine therapy of prostate cancer, in Fourth International Symposium on Transrectal Ultrasound in the Diagnosis and Management of Prostate Cancer, New York, Alan R. Liss Inc., pp 223-235. | Prostate Cancer | 1989 |
| 188. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Combination therapy with castration and flutamide: to-day's treatment of choice for prostate cancer. J. Steroid Biochem., 33: 817-821. | Prostate Cancer | 1989 |
| 189. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Combination therapy with Flutamide and castration: its benefits at various stages of prostate cancer, in: Murphy, G.P. et Khoury, S., eds: Progress in Clinical and Biological Research, New York, Alan R. Liss Inc., pp 161-167. | Prostate Cancer | 1989 |
| 190. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) LHRH agonists and prostate cancer: an example of rapid development of a new class of drugs, in: Chiou, S.H., Wang, K.T. et Wu, S.H., eds: International Symposium on Biologically Active Proteins and Peptides, July 13-15, 1988, Taipei, Taiwan, pp 129-136. | Prostate Cancer | 1989 |
| 191. Lacoste, D., Caron, S., Bélanger, A., Labrie, F. (1989) Effect of 3-week treatment with [D-Trp6, des-Gly-NH210]LHRH ethylamide, aminoglutethimide, ketoconazole or Flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog. J. Steroid Biochem., 33: 233-242. | Prostate Cancer | 1989 |
| 192. Lacoste, D., Dubé, D., Bélanger, A., Labrie, F. (1989) Effect of 2-week combination therapy with the LHRH agonist [D-Trp6,des-Gly-NH2]LHRH ethylamide and the antiandrogen Flutamide on prostate structure and steroid levels in the dog. Mol. Cell. Endocrinol., 67: 131-138. | Prostate Cancer | 1989 |
| 193. Lacoste, D., Dubé, D., Trudel, C., Bélanger, A., Labrie, F. (1989) Normal gonadal functions and fertility after 23 months of treatment of prepubertal male and female dogs with the GnRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide. J. Androl., 10: 456-465. | Prostate Cancer | 1989 |
| 194. Lacoste, D., Labrie, F., Dubé, D., Bélanger, A., Tice, T., Gilley, R.M., Pledger, K.L. (1989) Reversible inhibition of testicular androgen secretion by 3-, 5- and 6-month controlled-release microsphere formulations of the LHRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide in the dog. J. Steroid Biochem., 33: 1007-1011. | Prostate Cancer | 1989 |
| 195. Monfette, G., Dupont, A., Labrie, F. (1989) Temporary combination therapy with Flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 41-42. | Prostate Cancer | 1989 |
| 196. Monfette, G., Dupont, A., Pinault, S., Gagnon, J., Boivin, J.C., Têtu, B., Labrie, F. (1989) Advantages of downstaging local prostate cancer by 3-month combination therapy prior to radical prostatectomy, in Fourth International Symposium on Transrectal Ultrasound in the Diagnosis and Management of Prostate Cancer, New York, Alan R. Liss Inc., pp 255-261. | Prostate Cancer | 1989 |
| 197. Pinault, S., Gagnon, J., Monfette, G., Têtu, B., Dupont, A., Labrie, F. (1989) Transrectal ultrasound evaluation of local disease in prostate cancer patients treated with the combination therapy, in: Labrie, F., Lee, F. et Dupont, A., eds: Early State Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 53-62. | Prostate Cancer | 1989 |
| 198. Têtu, B., Labrie, F., Dupont, A., Monfette, G. (1989) Histopathologic effect of combination therapy on normal prostate and prostatic adenocarcinoma, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, Exerpta Medica ICS 841, pp 63-76. | Prostate Cancer | 1989 |
| 199. Bégin, D., Luthy, I.A., Labrie, F. (1988) Adrenal precursor C19 steroids are potent stimulators of growth of androgen-sensitive mouse mammary carcinoma Shionogi cells in vitro. Mol. Cell. Endocrinol., 58: 213-219. | Prostate Cancer | 1988 |
| 200. Bélanger, A., Giasson, M., Cliche, J., Dupont, A., Labrie, F. (1988) Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate, 12: 79-84. | Prostate Cancer | 1988 |
| 201. Belanger, A., Labrie, F., Dupont, A., Brochu, M., Cusan, L. (1988) Endocrine effects of combined treatment with an LHRH agonist in association with Flutamide in metastatic prostatic carcinoma. Clin. Invest. Med., 11: 321-326. | Prostate Cancer | 1988 |
| 202. Dubé, D., Pelletier, G., Labrie, F. (1988) The luteinizing hormone-releasing hormone (LHRH) agonist, [D-Trp6-des-Gly-NH2(10)]-LHRH ethylamide has no direct effect on spermatogenesis in the rat. Biol. Reprod., 38: 1165-1170. | Prostate Cancer | 1988 |